Metabolomic profiling reveals salivary hypotaurine as a potential early detection marker for medication-related osteonecrosis of the jaw.

导出 OA

翻译打印收藏纠错

作者： Wakako,Yatsuoka ^[1] ; Takao,Ueno ^[2] ; Kanako,Miyano ^[1] ; Yasuhito,Uezono ^[3] ; Ayame,Enomoto ^[3] ; Miku,Kaneko ^[4] ; Sana,Ota ^[5] ; Tomoyoshi,Soga ^[6] ; Masahiro,Sugimoto ^[6] ; Toshikazu,Ushijima ^[6]

作者单位： Dental Division, National Cancer Center Hospital, Tsukiji, Chuo-ku, Japan. ^[1] Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan. ^[2] Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tsukiji, Chuo-ku, Japan. ^[3] Division of Supportive Care Research, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tsukiji, Chuo-ku, Japan. ^[4] Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital, Tsukiji, Chuo-ku, Japan. ^[5] Institute for Advanced Biosciences, Keio University, Tsuruoka City, Yamagata, Japan. ^[6] Research and Development Center for Minimally Invasive Therapies Health Promotion and Preemptive Medicine, Tokyo Medical University, Shinjuku, Japan. ^[7] Division of Epigenomics, National Cancer Center Research Institute, Tsukiji, Chuo-ku, Japan. ^[8]